Narlumosbart is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Giant Cell Tumor Of Bone. According to GlobalData, Phase III drugs for Giant Cell Tumor Of Bone does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Narlumosbart LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Narlumosbart overview
Narlumosbart (Jinlisheng) is a recombinant humanized IgG4 monoclonal antibody acts as an anti-neoplastic agent. It is formulated as a solution for intravenous route of administration. Jinlisheng is indicated for the treatment of adult patients with giant cell tumor of bone that is unresectable or whose surgical resection is likely to result in severe functional impairment.
JMT-103 is under development for the treatment of refractory malignant hypercalcemia, bone metastasis, glucocorticoid-induced osteoporosis and postmenopausal osteoporosis. The drug candidate is administered through subcutaneous route. It is a monoclonal antibody that acts by targeting receptor activator of nuclear factor-kappa B ligand (RANKL).
CSPC Pharmaceutical Group overview
CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
For a complete picture of Narlumosbart’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
